Hepatic artery infusion chemotherapy for liver malignancy

Surgical Oncology Clinics of North America

Volumn 24, Issue 1, 2015, Pages 121-148

  Leal, Julie N ^a   Kingham, T Peter ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Liver metastases; Liver directed therapy; Primary liver cancer; Regional therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLOXURIDINE; FLUORESCEIN; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; IRINOTECAN; METHYLENE BLUE; MITOMYCIN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTERY CATHETER; ARTERY DISSECTION; ARTERY THROMBOSIS; BILE DUCT CARCINOMA; BILIARY SCLEROSIS; BILIARY TRACT DISEASE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CATHETER MIGRATION; CATHETER OCCLUSION; COLORECTAL LIVER METASTASIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ENZYME DEFECT; EROSION; EXTRAHEPATIC PERFUSION; HEMATOMA; HEPATIC ARTERY; HEPATIC ARTERY INFUSION CHEMOTHERAPY; HUMAN; HYPERBILIRUBINEMIA; INCOMPLETE HEPATIC PERFUSION; INFECTION; INFUSION PUMP; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; LIVER PERFUSION; LIVER RESECTION; MEDICAL DEVICE COMPLICATION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PROSTHESIS LOOSENING; PUMP MIGRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS; TOXIC HEPATITIS; TREATMENT OUTCOME; VOMITING; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS;

ANTINEOPLASTIC AGENTS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 84922933404     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.09.005     Document Type: Review

References (86)

1. Breedis C., Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30(5):969-977.
2. Sullivan R.D., Norcross J.W., Watkins E. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. NEngl J Med 1964, 270:321-327.
3. Cady B. Hepatic arterial patency and complications after catheterization for infusion chemotherapy. Ann Surg 1973, 178(2):156-161.
4. Ensminger W.D., Gyves J.W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983, 10(2):176-182.
5. Ensminger W.D. Regional chemotherapy. Semin Oncol 1993, 20(1):3-11.
6. Burrows J.H., Talley R.W., Drake E.H., et al. Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver. Cancer 1967, 20(11):1886-1892.
7. Clarkson B., Young C., Dierick W., et al. Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver. Cancer 1962, 15:472-488.
8. Ensminger W.D., et al. Aclinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 1978, 38(11 Pt 1):3784-3792.
9. Ensminger W.D., Rosowsky A., Raso V., et al. Hepatic arterial BCNU: a pilot clinical-pharmacologic study in patients with liver tumors. Cancer Treat Rep 1978, 62(10):1509-1512.
10. Kelsen D.P., Hoffman J., Alcock N., et al. Pharmacokinetics of cisplatin regional hepatic infusions. Am J Clin Oncol 1982, 5(2):173-178.
11. Garnick M.B., Ensminger W.D., Israel M. Aclinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res 1979, 39(10):4105-4110.
12. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. NEngl J Med 1999, 341(27):2039-2048.
13. Kingham T.P., D'Angelica M., Kemeny N.E. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. JSurg Oncol 2010, 102(8):988-995.
14. Arru M., Aldrighetti L., Gremmo F., et al. Arterial devices for regional hepatic chemotherapy: transaxillary versus laparotomic access. JVasc Access 2000, 1(3):93-99.
15. Urbach D.R., Herron D.M., Khajanchee Y.S., et al. Laparoscopic hepatic artery infusion pump placement. Arch Surg 2001, 136(6):700-704.
16. Franklin M.E., Gonzalez J.J. Laparoscopic placement of hepatic artery catheter for regional chemotherapy infusion: technique, benefits, and complications. Surg Laparosc Endosc Percutan Tech 2002, 12(6):398-407.
17. Franklin M., Trevino J., Hernandez-Oaknin H., et al. Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease?. Surg Endosc 2006, 20(4):554-558.
18. Hellan M., Pigazzi A. Robotic-assisted placement of a hepatic artery infusion catheter for regional chemotherapy. Surg Endosc 2008, 22(2):548-551.
19. Blackshear P.J., Rohde T.D., Dorman F.D., et al. An implantable pump for long-term intravascular drug infusion. Med Instrum 1981, 15(4):226-228.
20. Buchwald H., Grage T.B., Vassilopoulos P.P., et al. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 1980, 45(5):866-869.
21. Heinrich S., Petrowsky H., Schwinnen I., et al. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery 2003, 133(1):40-48.
22. Fordy C., Burke D., Earlam S., et al. Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Cancer 1995, 72(4):1023-1025.
23. Bacchetti S., Pasqual E., Crozzolo E., et al. Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: a review of medical devices complications in 3172 patients. Med Devices (Auckl) 2009, 2:31-40.
24. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. JNatl Cancer Inst 1997, 89(7):497-505.
25. James R.D., on behalf of the AXIS collaborators Intraportal 5FU (PVI) and peri-operative radiotherapy (RT) in the adjuvant treatment of colorectal cancer (CRCa)-3681 patients randomised in the UK Coordinating Committee on Cancer Research (UKCCCR) AXIS trial. Proc Am Soc Clin Oncol 1999, 18:1013. [abstract].
26. Labianca R., Boffi L., Marsoni S., et al. Arandomized trial of intraportal (IP) versus systemic (SY) versus IP+ SY adjuvant chemotherapy in patients (pts) with resected Dukes B-C colon carcinoma (CC). Proc Am Soc Clin Oncol 1999, 18:1014. [abstract].
27. Rougier P., Sahmoud T., Nitti D., et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998, 351(9117):1677-1681.
28. Laffer U, Maibach R, Metzger U, etal. Randomized trial of adjuvant perioperative chemotherapy in radically resected colorectal cancer (SAKK 40/87). Proc Am Soc Clin Oncol 17:983, [abstract].
29. Cohen A.D., Kemeny N.E. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003, 8(6):553-566.
30. Skitzki J.J., Chang A.E. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol 2002, 11(3):123-135.
31. Kemeny M.M. The surgical aspects of the totally implantable hepatic artery infusion pump. Arch Surg 2001, 136(3):348-352.
32. Saba L., Mallarini G. Multidetector row CT angiography in the evaluation of the hepatic artery and its anatomical variants. Clin Radiol 2008, 63(3):312-321.
33. Grobmyer S.R., Fong Y., D'Angelica M., et al. Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. Arch Surg 2004, 139(12):1326-1330.
34. Michels N.A. Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg 1966, 112(3):337-347.
35. Kemeny M.M., Hogan J.M., Goldberg D.A., et al. Continuous hepatic artery infusion with an implantable pump: problems with hepatic artery anomalies. Surgery 1986, 99(4):501-504.
36. Rayner A.A., Kerlan R.K., Stagg R.J., et al. Total hepatic arterial perfusion after occlusion of variant lobar vessels: implications for hepatic arterial chemotherapy. Surgery 1986, 99(6):708-715.
37. Allen P.J., Nissan A., Picon A.I., et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. JAm Coll Surg 2005, 201(1):57-65.
38. Curley S.A., Chase J.L., Roh M.S., et al. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 1993, 114(5):928-935.
39. Kemeny N., Seiter K., Niedzwiecki D., et al. Arandomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992, 69(2):327-334.
40. Patt Y.Z., Mavligit G.M., Chuang V.P., et al. Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): an effective treatment for metastatic colorectal carcinoma in the liver. Cancer 1980, 46(2):261-265.
41. Kemeny N., Daly J., Oderman P., et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. JClin Oncol 1984, 2(6):595-600.
42. Niederhuber J.E., Ensminger W., Gyves J., et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984, 53(6):1336-1343.
43. Sofocleous C.T., Schubert J., Kemeny N., et al. Arterial embolization for salvage of hepatic artery infusion pumps. JVasc Interv Radiol 2006, 17(5):801-806.
44. Roybal J.J., Feliberti E.C., Rouse L., et al. Pump removal in infected patients with hepatic chemotherapy pumps: when is it necessary?. Am Surg 2006, 72(10):880-884.
45. Barnett K.T., Malafa M.P. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer 2001, 30(3):147-160.
46. Ito K., Ito H., Kemeny N.E., et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012, 19(5):1609-1617.
47. Cercek A., D'Angelica M., Power D., et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol 2014, 21(2):479-486.
48. Lorenz M., Muller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998, 228(6):756-762.
49. Rudroff C., Altendorf-Hoffmann A., Stangl R., et al. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999, 384(3):243-249.
50. Kemeny N.E., Gonen M. Hepatic arterial infusion after liver resection. NEngl J Med 2005, 352(7):734-735.
51. Kemeny M.M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. JClin Oncol 2002, 20(6):1499-1505.
52. Kemeny N., Jarnagin W., Gonen M., et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. JClin Oncol 2003, 21(17):3303-3309.
53. Kemeny N., Capanu M., D'Angelica M., et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009, 20(7):1236-1241.
54. Kemeny N.E., Jarnagin W.R., Capanu M., et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. JClin Oncol 2011, 29(7):884-889.
55. Alberts S.R., Roh M.S., Mahoney M.R., et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. JClin Oncol 2010, 28(5):853-858.
56. Tomlinson J., Jarnagin W., DeMatteo R., et al. Actual 10-year survival after resection of colorectal liver metastases. JClin Oncol 2007, 25:4575-4582.
57. Ito H., Are C., Gonen M., et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008, 247(6):994-1002.
58. House M.G., Kemeny N.E., Gonen M., et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 2011, 254(6):851-856.
59. Goere D., Benhaim L., Bonnet S., et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 2013, 257(1):114-120.
60. Chang A.E., Schneider P.D., Sugarbaker P.H., et al. Aprospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206(6):685-693.
61. Kemeny N., Daly J., Reichman B., et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987, 107(4):459-465.
62. Hohn D.C., Stagg R.J., Friedman M.A., et al. Arandomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. JClin Oncol 1989, 7(11):1646-1654.
63. Wagman L.D., Kemeny M.M., Leong L., et al. Aprospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. JClin Oncol 1990, 8(11):1885-1893.
64. Martin J.K., O'Connell M.J., Wieand H.S., et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990, 125(8):1022-1027.
65. Rougier P., Laplanche A., Huguier M., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. JClin Oncol 1992, 10(7):1112-1118.
66. Allen-Mersh T.G., Earlam S., Fordy C., et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344(8932):1255-1260.
67. Lorenz M., Muller H.H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. JClin Oncol 2000, 18(2):243-254.
68. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003, 361(9355):368-373.
69. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). JClin Oncol 2006, 24(9):1395-1403.
70. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. JNatl Cancer Inst 1996, 88(5):252-258.
71. Mocellin S., Pilati P., Lise M., et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. JClin Oncol 2007, 25(35):5649-5654.
72. Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol 2010, 22(4):364-373.
73. Allen-Mersh T.G., Glover C., Fordy C., et al. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol 2000, 26(5):468-473.
74. Kemeny N., Gonen M., Sullivan D., et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. JClin Oncol 2001, 19(10):2687-2695.
75. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. JClin Oncol 2005, 23(22):4888-4896.
76. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008, 15(1):219-226.
77. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of thegastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. JClin Oncol 2005, 23(22):4881-4887.
78. Power D.G., Kemeny N.E. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol 2011, 79(3):251-264.
79. Ammori J.B., Kemeny N.E., Fong Y., et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol 2013, 20(9):2901-2907.
80. Goere D., Deshaies I., de Baere T., et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010, 251(4):686-691.
81. Jarnagin W.R., Schwartz L.H., Gultekin D.H., et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009, 20(9):1589-1595.
82. Kemeny N.E., Schwartz L., Gonen M., et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?. Oncology 2011, 80(3-4):153-159.
83. Konstantinidis I.T., Do R.K., Gultekin D.H., et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol 2014, 21(8):2675-2683.
84. Leyvraz S., Spataro V., Bauer J., et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. JClin Oncol 1997, 15(7):2589-2595.
85. Melichar B., Voboril Z., Lojik M., et al. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology 2009, 56(93):1157-1162.
86. Tsimberidou A.M., Moulder S., Fu S., et al. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 2010, 66(6):1087-1093.